Wednesday - May 16, 2018

New services launched in Manchester bring vital eye care to the high street

Formally opened today by Andy Burnham, Mayor of Greater Manchester, the two community based services in North and South Manchester are the result of a joint working partnership between Manchester University NHS Foundation Trust and Bayer

In a joint working partnership, Manchester University NHS Foundation Trust and Bayer, have successfully launched two new community-based services in North and South Manchester, for people diagnosed with retinal conditions. The new high street-based services, located in Cheetham Hill shopping centre in North Manchester and Wythenshawe Civic Centre in South Manchester, support the request by local commissioners for more care in the community and will improve the overall experience for patients by bringing much needed eye care to convenient locations. Importantly, the additional locations will also increase the number of available appointments, which will help to minimise delays to sight-preserving treatments.

In Manchester alone, nearly 3000 patients per month require review and assessment for treatment of sight-threatening macular disease. The growing demand for eye care services was negatively impacting the ability to offer timely follow-up appointments in line with guidance from the National Institute for Clinical Excellence (NICE) and the Royal College of Ophthalmologists. Furthermore, with the service covering a 30 mile radius, accessibility to hospital-based appointments was also a significant hurdle for patients.

"Our priority is always to ensure the highest standard of care, at every stage of the treatment journey, for patients accessing our services. While diagnostic and initial treatment appointments were meeting these standards, we needed to make sure that New services launched in Manchester bring vital eye care to the high street Formally opened today by Andy Burnham, Mayor of Greater Manchester, the two community based services in North and South Manchester are the result of a joint working partnership between Manchester University NHS Foundation Trust and Bayer patients continued to receive the best level of care with timely follow-up appointments,” explained Dr Sajjad Mahmood, Consultant Ophthalmologist, Manchester Royal Eye Hospital. “The new services not only respond to this need, but also provide significant benefits for our large patient community with vital care in convenient, close-to-home locations."

The two new services, offer state-of-the-art facilities that are easily accessible by public transport, with ample free car parking. The one-stop assessment and treatment service also aims for the average appointment attendance time to be under an hour. Given the long-term need for patients with sight-threatening eye conditions to attend regular followup appointments,1 the convenience and service efficiencies will translate to less time spent attending and travelling to and from appointments.

Commenting on Bayer’s contribution to the Manchester University NHS Foundation Trust joint working project, Dr Nitin Jain, Senior Medical Advisor, Bayer, noted "Responding to the needs of patients is always at the core of our commitment to working with NHS Trusts to improve the delivery of ophthalmology services. We are proud to partner with Manchester University NHS Foundation Trust on a project that has been built on better serving people with retinal conditions in Greater Manchester, providing convenient and prompt access to the highest level of care."

The Cheetham Hill service, was formally launched by Andy Burnham, Mayor of Greater Manchester at a launch event today.

Karen Tait, +44 118 206 3521

Manchester University NHS Foundation Trust:
Karen Moore, +44 161 701 7579 / +44 7966 559068

Notes to Editors
About retinal conditions
Some of the most common causes of vision loss include eye conditions such as wet AMD and DMO. 2,3 These are conditions that impact the central part of the retina at the back of the eye, called the macula.4 They are caused by the growth of abnormal and fragile blood vessels beneath the macula that bleed and leak causing problems with central vision.5 The macula is the part of the eye responsible for sharp, central vision which allows us to see objects clearly, in detail, right in front of us.4

About Bayer
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to

About MFT Manchester University NHS Foundation Trust is one of the largest NHS Trusts in the country and a leading provider of specialist healthcare services. Its nine hospitals are home to hundreds of world class clinicians and academic staff committed to finding and providing patients with the best care and treatments.

The nine hospitals in the MFT group are Manchester Royal Infirmary, Saint Mary's Hospital, Royal Manchester Children's Hospital, Manchester Royal Eye Hospital, University Dental Hospital of Manchester, Trafford General, Altrincham Hospital, Wythenshawe Hospital, and Withington Hospital. More information is available at


1. Thompson AC, Thompson MO, Young DL et al. Barriers to Follow-Up and Strategies to Improve Adherence to Appointments for Care of Chronic Eye Diseases. IOVS. 56 (2015), 4324 - 4331

2. Diabetic macular oedema. Moorfields NHS. Available at: (Last accessed May 2018)

3. Kulkarni AD, Kuppermann BD. Wet age-related macular degeneration. Advanced Drug Delivery Reviews. 57 (2005) 1994– 2009

4. Liew G et al. Comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000. BMJ Open 2014;4:e004015. doi:10.1136/bmjopen-2013- 004015

5. RNIB. Age-related macular degeneration. Available at: (Last accessed: May 2018)